
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

ODYSSEY THERAPEUTICS, INC.

(Name of Issuer)

COMMON STOCK, \$0.0001 par value per share

(Title of Class of Securities)

(CUSIP Number)

Rafaele Tordjman
37 rue de la Victoire,
Paris, IO, 75009
33603354757

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/08/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

Name of reporting person

1

Jeito II S.L.P.

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

4 Source of funds (See Instructions)

WC

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6 Citizenship or place of organization

FRANCE

Sole Voting Power

7

Number of Shares Beneficially Owned by Each Reporting Person With:

8 0.00

9 Shared Voting Power

3,690,145.00

10 Sole Dispositive Power

0.00

11 Shared Dispositive Power

3,690,145.00

12 Aggregate amount beneficially owned by each reporting person

3,690,145.00

13 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

14 Percent of class represented by amount in Row (11)

7.8 %

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage in row 13 is calculated based on 47,174,156 shares of common stock, reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026.

SCHEDULE 13D

CUSIP No.

1 Name of reporting person

Jeito Capital SAS

Check the appropriate box if a member of a Group (See Instructions)

2 (a)

(b)

3 SEC use only

4 Source of funds (See Instructions)

OO

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6 Citizenship or place of organization

FRANCE

Number of 7 Sole Voting Power

Shares Beneficially Owned by Each Reporting Person With: 0.00
 Shared Voting Power
 8
 3,690,145.00
 Sole Dispositive Power
 9
 0.00
 Shared Dispositive Power
 10
 3,690,145.00
 Aggregate amount beneficially owned by each reporting person
 11
 3,690,145.00
 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
 12

 Percent of class represented by amount in Row (11)
 13
 7.8 %
 Type of Reporting Person (See Instructions)
 14
 IA

Comment for Type of Reporting Person: The percentage in row 13 is calculated based on 47,174,156 shares of common stock, reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026.

SCHEDULE 13D

CUSIP No.

1 Name of reporting person
 Raffaele Tordjman
 Check the appropriate box if a member of a Group (See Instructions)
 2
 (a)
 (b)
 3 SEC use only
 Source of funds (See Instructions)
 4
 OO
 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
 5

 Citizenship or place of organization
 6
 FRANCE
 Number of Shares Beneficially Owned by Each Reporting Person With: Sole Voting Power
 7
 0.00
 Shared Voting Power
 8
 3,690,145.00
 Sole Dispositive Power
 9
 0.00
 10 Shared Dispositive Power

3,690,145.00

Aggregate amount beneficially owned by each reporting person

11

3,690,145.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

7.8 %

Type of Reporting Person (See Instructions)

14

IN

Comment for Type of Reporting Person: The percentage in row 13 is calculated based on 47,174,156 shares of common stock, reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026.

SCHEDULE 13D

CUSIP No.

Name of reporting person

1

Sabine Dandiguian

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

OO

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

FRANCE

Sole Voting Power

7

0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

Shared Voting Power

8

3,690,145.00

Sole Dispositive Power

9

0.00

Shared Dispositive Power

10

3,690,145.00

Aggregate amount beneficially owned by each reporting person

11

3,690,145.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

7.8 %

IN

Comment for Type of Reporting Person: The percentage in row 13 is calculated based on 47,174,156 shares of common stock, reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026.

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a) COMMON STOCK, \$0.0001 par value per share

Name of Issuer:

(b) ODYSSEY THERAPEUTICS, INC.

Address of Issuer's Principal Executive Offices:

(c) 51 SLEEPER STREET, SUITE 800, BOSTON, MASSACHUSETTS , 02210.

Item 2. Identity and Background

This Schedule 13D is being jointly filed by Jeito II S.L.P., Jeito Capital SAS, Rafaele Tordjman and Sabine Dandiguian (together, the "Reporting Persons"). Rafaele Tordjman and Sabine Dandiguian disclaim beneficial ownership over the shares of common stock described herein, except to the extent of their pecuniary interest therein.

(b) The business address of each of the Reporting Persons is: 37 rue de la Victoire 75009 Paris France

(c) Jeito II S.L.P. is a private investment fund. Jeito Capital SAS is the management company of Jeito II S.L.P. Rafaele Tordjman is the Chief Executive Officer of Jeito Capital SAS. Sabine Dandiguian is the Managing Director of Jeito Capital SAS.

(d) During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding.

(e) During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Jeito II S.L.P. is a French limited partnership ("societe de libre partenariat"). Jeito Capital SAS is a French limited liability company ("societe par actions simplifiee"). Rafaele Tordjman and Sabine Dandiguian are citizens of France.

Item 3. Source and Amount of Funds or Other Consideration

In connection with the closing of the initial public offering (the "IPO") of the Issuer on May 11, 2026, 18,272,789 shares of Series D convertible preferred stock and one common stock warrant exercisable for 4,111,377 shares of common stock held by Jeito II S.L.P. automatically converted into 1,880,497 and 420,760 shares of common stock of the Issuer, respectively. Jeito II S.L.P. purchased 1,388,888 shares of common stock at a price of \$18.00 per share in the IPO. The funds to purchase the securities of the Issuer described in this Item 3 were furnished from working capital of Jeito II S.L.P.

Item 4. Purpose of Transaction

Jeito II S.L.P. acquired the shares of common stock as described in this Schedule 13D for investment purposes in the regular course of its business. Jeito Capital SAS, as the management company of Jeito II S.L.P., may be deemed to be a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Act"), of any securities held by Jeito II S.L.P. Rafaele Tordjman, as Chief Executive Officer of Jeito Capital SAS, and Sabine Dandiguian, as Managing Director of Jeito Capital SAS, may be deemed to be beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by Jeito Capital SAS. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on market conditions, liquidity requirements, the continuing evaluation of the business and prospects of the Issuer and other factors, the Reporting Persons may dispose of or acquire additional shares of common stock of the Issuer. Ksenija Pavletic, who is the General Partner and Chief Commercial Officer at Jeito Capital SAS, is a director of the Issuer. The Reporting Persons, either directly or indirectly through Ms. Pavletic, may engage in discussions from time to time with the Board, the Issuer's management or the Issuer's other stockholders, including discussions that may relate to the items described in clauses (a) through (j) of Item 4 of Schedule 13D. Except as set forth in this Item 4 or Item 6 below, the Reporting Persons have no present plans or proposals that relate to or that would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer

(a) Jeito II S.L.P. holds 3,690,145 shares of common stock, representing approximately 7.8% of the Issuer's outstanding shares of common stock, based upon 47,174,156 shares of common stock reported to be outstanding in the Issuer's

Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026. Jeito Capital SAS is the management company of Jeito II S.L.P. As a result, Jeito Capital SAS shares power to direct the vote and disposition of the shares held by Jeito II S.L.P. and may be deemed to be the beneficial owner of the shares held by Jeito II S.L.P. Rafael Tordjman, as Chief Executive Officer of Jeito Capital SAS, and Sabine Dandiguan, as Managing Director of Jeito Capital SAS, may be deemed to be beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by Jeito Capital SAS.

- (b) Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D set forth the number of shares of common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or direct the disposition and are incorporated by reference.
- (c) The response to Item 3 of this Schedule 13D is incorporated herein by reference.
- (d) No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of common stock subject to this Schedule 13D.
- (e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

On April 7, 2026, in connection with the Issuer's IPO, Jeito II S.L.P. entered into a lock-up agreement (the "Lock-Up Agreement") with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters. Pursuant to the Lock-Up Agreement, Jeito II S.L.P. has agreed that, subject to certain exceptions, it will not, for a period of 180 days following May 7, 2026, the date of the Issuer's prospectus filed pursuant to Rule 424(b)(4) with the SEC, without the prior written consent of the representatives, (i) offer, sell, contract to sell, pledge, grant any option, right or warrant to purchase, purchase any option or contract to sell, lend or otherwise transfer or dispose of any shares of common stock, or any options or warrants to purchase any shares of common stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of common stock (collectively, "Lock-Up Securities"), including without limitation any such Lock-Up Securities then owned or thereafter acquired, (ii) engage in any hedging or other transaction or arrangement or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of common stock or other securities, in cash or otherwise, (iii) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities or (iv) otherwise publicly announce any intention to engage in or cause any action, activity, transaction or arrangement described above. The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to such, which form is filed as an exhibit and incorporated herein by reference. Jeito II S.L.P. is a party to that certain Investors' Rights Agreement, as amended and restated on June 16, 2025, by and among the Issuer and certain of its stockholders named therein (the "IRA"). Pursuant to the terms of the IRA, beginning 180 days after May 7, 2026, the effective date of the registration statement for the Issuer's IPO, holders of a majority of the then-outstanding Registrable Securities (as defined therein) have the right to require the Issuer to file a Form S-1 registration statement to register at least 40% of the then-outstanding Registrable Securities with an anticipated aggregate offering price of at least \$10 million, subject to customary terms and conditions. At any time the Issuer is eligible to use a Form S-3 registration statement, the holders who are party to the IRA and who collectively hold at least 25% of then-outstanding Registrable Securities have the right to require the Issuer to file a registration statement on Form S-3 to register outstanding Registrable Securities of such holders having an anticipated aggregate offering price of at least \$5 million, subject to customary terms and conditions. Under the IRA, holders of Registrable Securities are entitled to piggyback registration rights, subject to customary terms and conditions. The foregoing description of the IRA does not purport to be complete and is qualified in its entirety by reference to such, which is filed as an exhibit and incorporated herein by reference.

Item 7. Material to be Filed as Exhibits.

Exhibit 99.1: Joint Filing Agreement. Exhibit 99.2: Form of Lock-Up Agreement (incorporated by reference to Annex II to the Form of Underwriting Agreement filed as Exhibit 1.1 to the Issuer's Registration Statement on Form S-1/A (Registration No. 333-295141), filed with the Securities and Exchange Commission on May 4, 2026). Exhibit 99.3: Third Amended and Restated Investors' Rights Agreement, dated June 16, 2025, by and among the Issuer and the investors thereto, as amended (incorporated by reference to Exhibit 4.3 to the Issuer's Registration Statement on Form S-1/A (Registration No. 333-295141), filed with the Securities and Exchange Commission on May 4, 2026).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Jeito II S.L.P.

Signature: /s/ Rafael Tordjman

Name/Title: Rafael Tordjman, CEO of Jeito Capital SAS
acting as management company of Jeito II S.L.P.

Date: 05/15/2026

Jeito Capital SAS

Signature: /s/ Rafael Tordjman

Name/Title: Rafaele Tordjman, CEO

Date: 05/15/2026

Rafaele Tordjman

Signature: /s/ Rafaele Tordjman

Name/Title: Rafaele Tordjman

Date: 05/15/2026

Sabine Dandiguan

Signature: /s/ Sabine Dandiguan

Name/Title: Sabine Dandiguan

Date: 05/15/2026

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing of a Statement on Schedule 13D (including amendments thereto) with respect to the common stock of Odyssey Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit thereto. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement this 15th day of May, 2026.

JEITO II S.L.P.

By: /s/ Rafaele Tordjman
Rafaele Tordjman, CEO of Jeito Capital SAS acting as management company of Jeito II S.L.P.

JEITO CAPITAL SAS

By: /s/ Rafaele Tordjman
Rafaele Tordjman, CEO

RAFAELE TORDJMAN

By: /s/ Rafaele Tordjman

SABINE DANDIGUIAN

By: /s/ Sabine Dandiguian
